[1] |
Aalen, O., Borgan, O., & Gjessing, H. (2008). Survival and event history analysis. Berlin, Germany: Springer Science & Business Media. · Zbl 1204.62165 |
[2] |
Aalen, O., & Johansen, S. (1978). An empirical transition matrix for non‐homogeneous Markov chains based on censored observations. Scandinavian Journal of Statistics, 5, 141-150. · Zbl 0383.62058 |
[3] |
Allignol, A., Beyersmann, J., & Schumacher, M. (2011). mvna: An R package for the Nelson-Aalen estimator in multistate models. R News, 8, 48-50. |
[4] |
Allignol, A., Beyersmann, J., & Schmoor, C. (2016). Statistical issues in the analysis of adverse events in time‐to‐event data. Pharmaceutical Statistics, 15, 297-305. |
[5] |
Allignol, A., Schumacher, M., & Beyersmann, J. (2011). Empirical transition matrix of multi‐state models: The etm package. Journal of Statistical Software, 38, 1-15. |
[6] |
Altman, D. G., & Bland, J. M. (1983). Measurement in medicine: the analysis of method comparison studies. Journal of the Royal Statistical Society. Series D (The Statistician), 32, 307-317. http://www.jstor.org/stable/2987937. |
[7] |
Andersen, P. K. (1983). Comparing survival distributions via hazard ratio estimates. Scandinavian Journal of Statistics, 10, 77-85. · Zbl 0526.62043 |
[8] |
Andersen, P. K., Angst, J., & Ravn, H. (2019). Modeling marginal features in studies of recurrent events in the presence of a terminal event. Lifetime Data Analysis, 25, 681-695. · Zbl 1436.62505 |
[9] |
Andersen, P. K., Borgan, O., Gill, R. D., & Keiding, N. (1993). Statistical models based on counting processes. Berlin, Germany: Springer Science & Business Media. · Zbl 0769.62061 |
[10] |
Bender, R., & Beckmann, L. (2019). Limitations of the incidence density ratio as approximation of the hazard ratio. Trials, 20, 485. |
[11] |
Bender, R., Beckmann, L., & Lange, S. (2016). Biometrical issues in the analysis of adverse events within the benefit assessment of drugs. Pharmaceutical Statistics, 15, 292-296. |
[12] |
Bender, R., Friede, T., Koch, A., Kuss, O., Schlattmann, P., Schwarzer, G., & Skipka, G. (2018). Methods for evidence synthesis in the case of very few studies. Research Synthesis Methods, 9, 382-392. |
[13] |
Beyersmann, J., & Schmoor, C. (2019). The analysis of adverse events in randomized clinical trials. In S.Halabi (ed.) & S.Michiels (ed.) (Eds.), Textbook of clinical trials in oncology: a statistical perspective, (537-558). Boca Raton, FL: CRC Press. |
[14] |
Beyersmann, J., & Schrade, C. (2017). Florence Nightingale, William Farr and competing risks. Journal of the Royal Statistical Society: Series A (Statistics in Society), 180, 285-293. |
[15] |
Committee for Human Medicinal Products (2016). Guideline for good clinical practice E6(R2). Retrieved from https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice#current-version-revision-2-section. |
[16] |
Crowe, B. J., Xia, H. A., Berlin, J. A., Watson, D. J., Shi, H., Lin, S. L., .. et al,. (2009). Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: A report of the safety planning, evaluation, and reporting team. Clinical Trials, 6, 430-440. |
[17] |
EMA (2009). A guideline on summary of product characteristics (SmPC). Retrieved from https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. |
[18] |
Ferreira‐González, I., Permanyer‐Miralda, G., Busse, J. W., Bryant, D. M., Montori, V. M., Alonso‐Coello, P., … Gordon, H. Guyatt (2017). Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. Journal of Clinical Epidemiology, 60, 651-657. |
[19] |
Gill, R. D., & Johansen, S. (1990). A survey of product‐integration with a view toward application in survival analysis. The Annals of Statistics, 18, 1501-1555. · Zbl 0718.60087 |
[20] |
Gosho, M., Sato, Y., Nagashima, K., & Takahashi, S. (2018). Trends in study design and the statistical methods employed in a leading general medicine journal. Journal of Clinical Pharmacy and Therapeutics, 43, 36-44. |
[21] |
Gould, A.L. (2018). Unified screening for potential elevated adverse event risk and other associations. Statistics in Medicine, 37, 2667-2689. |
[22] |
Günhan, B.K., Röver, C., & Friede, T. (2020). Meta‐analysis of few studies involving rare events. Research Synthesis Methods, 11, 74-90. |
[23] |
Hedges, L. V., & Olkin, I. (2014). Statistical methods for meta‐analysis. New York: Academic press. |
[24] |
Hjort, N. (1992). On inference in parametric survival data models. International Statistical Review, 60, 355-387. · Zbl 0762.62009 |
[25] |
Horton, N., & Switzer, S. (2005). Statistical methods in the journal. New England Journal of Medicine, 353, 1977-1979. |
[26] |
IQWiG (2017). Allgemeine Methoden, Version 5.0. Institute of Quality and Efficiency in Health Care. Retrieved from https://www.iqwig.de/de/methoden/methodenpapier.3020.html. |
[27] |
Kieser, M., & Hauschke, D. (2005). Assessment of clinical relevance by considering point estimates and associated confidence intervals. Pharmaceutical Statistics: The Journal of Applied Statistics in the Pharmaceutical Industry, 4, 101-107. |
[28] |
Kraemer, H. C. (2009). Events per person‐time (incidence rate): a misleading statistic?Statistics in Medicine, 28, 1028-1039. |
[29] |
Krouwer, J. S. (2008). Why Bland-Altman plots should use X, not (Y+ X)/2 when X is a reference method. Statistics in Medicine, 27, 778-780. |
[30] |
Lacny, S., Wilson, T., Clement, F., Roberts, D. J., Faris, P., Ghali, W., & Marshall, D. (2015). Kaplan‐Meier survival analysis overestimates the risk of revision arthroplasty: a meta‐analysis. Clinical Orthopaedics and Related Research, 473, 3431-3442. |
[31] |
Lacny, S., Wilson, T., Clement, F., Roberts, D. J., Faris, P., Ghali, W., & Marshall, D. (2018). Kaplan‐Meier survival analysis overestimates cumulative incidence of health‐related events in competing risk settings: a meta‐analysis. Journal of Clinical Epidemiology, 93, 25-35. |
[32] |
Lawless, J. F., & Cook, R. J. (2019). A new perspective on loss to follow‐up in failure time and life history studies. Statistics in Medicine, 38, 4583-4610. |
[33] |
O’Neill, R. T. (1987). Statistical analyses of adverse event data from clinical trials: Special emphasis on serious events. Drug Information Journal, 21, 9-20. |
[34] |
Pocock, S. J., Clayton, T. C., & Altman, D. G. (2002). Survival plots of time‐to‐event outcomes in clinical trials: Good practice and pitfalls. The Lancet, 359, 1686-1689. |
[35] |
R Core Team (2018). R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. Retrieved from https://www.R-project.org/. |
[36] |
Rufibach, K. (2019). Treatment effect quantification for time‐to‐event endpoints – estimands, analysis strategies, and beyond. Pharmaceutical Statistics, 18, 145-165. |
[37] |
Sato, Y., Gosho, M., Nagashima, K., Takahashi, S., Ware, J. H., & Laird, N. M. (2017). Statistical methods in the journal—An update. New England Journal of Medicine, 376, 1086-1087. |
[38] |
Schumacher, M., Ohneberg, K., & Beyersmann, J. (2016). Competing risk bias was common in a prominent medical journal. Journal of Clinical Epidemiology, 80, 135-136. |
[39] |
Siddiqui, O. (2009). Statistical methods to analyze adverse events data of randomized clinical trials. Journal of Biopharmaceutical Statistics, 19, 889-899. |
[40] |
Therneau, T. M., & Grambsch, P. M. (2000). Modeling survival data: extending the Cox model. Berlin, Germany: Springer Science & Business Media. · Zbl 0958.62094 |
[41] |
Unkel, S., Amiri, M., Benda, N., Beyersmann, J., Knoerzer, D., Kupas, K., .. Friede, T. (2019). On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies. Pharmaceutical Statistics, 18, 166-183. |
[42] |
van derVaart, A. W. (1998). Asymptotic statistics. Cambridge, UK: Cambridge University Press. · Zbl 0910.62001 |
[43] |
vanWalraven, C., & McAlister, F. A. (2016). Competing risk bias was common in Kaplan‐Meier risk estimates published in prominent medical journals. Journal of Clinical Epidemiology, 69, 170-173. |
[44] |
Veroniki, A.A., Jackson, D., Bender, R., Kuss, O., Langan, D., Higgins, J.P.T., .. Salanti, G. (2019). Methods to calculate uncertainty in the estimated overall effect size from a random effects meta analysis. Research Synthesis Methods, 10, 23-43. |
[45] |
Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., & Salanti, G. (2016). Methods to estimate the between‐study variance and its uncertainty in meta‐analysis. Research Synthesis Methods, 7, 55-79. |
[46] |
Viechtbauer, W. (2010). Conducting meta‐analyses in R with the metafor package. Journal of Statistical Software, 36, 1-48. |
[47] |
Windeler, J., & Lange, S. (1995). Events per person year—A dubious concept. British Medical Journal, 310, 454-456. |
[48] |
Yang, F., Wittes, J., & Pitt, B. (2019). Beware of on‐treatment safety analyses. Clinical Trials, 16, 63-70. https://doi.org/10.1177/1740774518812774, pMID: 30445833. · doi:10.1177/1740774518812774 |